Loading clinical trials...
Loading clinical trials...
A PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS
Conditions
Interventions
PD 0360324
Normal Saline for injection
Locations
5
United States
Mount Sinai School Of Medicine/Mount Sinai Medical Center
New York, New York, United States
Medical Arts Building
Cincinnati, Ohio, United States
The Barrett Cancer Center at UC Health
Cincinnati, Ohio, United States
University Hospital
Cincinnati, Ohio, United States
Iinterstitial Lung Disease & Sarcoidosis Clinic
Cincinnati, Ohio, United States
Start Date
March 15, 2013
Primary Completion Date
September 23, 2013
Completion Date
September 23, 2013
Last Updated
January 6, 2020
NCT06169397
NCT04064242
NCT06113991
NCT03599414
NCT01587001
NCT02188017
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions